Follow us on
Search News Archives
Conferences | Events
Lab Bulletin Media Partners

Finnish Biomedical Start-Up Nightingale Health Obtains CE Mark for Blood Analysis Platform

publication date: Jul 27, 2017
 | 
author/source: Nightingale Health

Finnish biomedical startup Nightingale Health Ltd announced today CE marking for its blood biomarker analysis platform.

nightingale imageThe CE mark enables the clinical use of the analysis service and the analysed measures of creatinine and glucose in the EU region. 

Nightingale’s goal is to bring dozens of biomarkers included in the analysis platform gradually available for clinical use within the next year. The obtained CE mark is a remarkable step towards the company’s aim, enabling better prediction and targeted care for chronic diseases. 

Nightingale Health's blood biomarker analysis platform is based on NMR (Nuclear Magnetic Resonance) spectroscopy. It captures over 228 metabolic biomarkers from a single blood sample, transforming the possibility to understand molecular mechanisms and treatment effects of chronic diseases, such as cardiovascular disease, diabetes, and other metabolic diseases. To date, Nightingale Health’s blood biomarker analysis platform has been used by world leading medical universities and institutions and nearly half a million blood samples have been analysed with the technology. Nightingale Health’s quality management system has previously been certified according to EN ISO 13485 standard.

“The CE mark verifies the performance, reliability and repeatability of our blood analysis technology for clinical use according to our quality management system. We expect a rapid entry to the clinical market across Europe”, says Mr. Teemu Suna, Nightingale Health’s CEO and Co-founder. “We believe that our technology takes us one step closer to better prevention of chronic diseases. Therefore, we see this as a notable milestone, not only for our company but also for preventive medicine.”

Diabetes and cardiovascular diseases are one of the world’s biggest health problems. The global burden of diabetes has been evaluated at US $ 1.31 trillion, equivalent of 0,6 % of the world’s GDP.

Nightingale Health’s blood biomarker analysis platform

Nightingale Health’s biomarker analysis platform provides quantification of 228 metabolic measures from single sample with one test. The metabolites are quantified in absolute concentrations (e.g. mmol/l), so they can be applied both in healthcare and in medical research. The method is fully feasible for diagnostic use of individual biomarkers, research of multiple biomarker metabolic pathways, and the risk analytics of comprehensive metabolic diseases. The now obtained CE mark covers the clinical use of creatinine and glucose measures.


more about nightingale


 



 

Popular this month


 

Win an INTEGRA VOYAGER adjustable tip spacing pipette


Thermo Fisher Scientific Announces Collaboration to Simplify Analysis of Complex Therapeutic Proteins


World’s first high throughput microplate reader for circular dichroism


Eppendorf Presents First Internally Developed CO2 Incubator


Thinking about buying a LIMS? Pick wisely!


Lab Innovations 2018 confirmed as a major hit with visitors, exhibitors and speakers


Take your microwell plate pipetting to the next level!


ZEISS and arivis AG Intensify Strategic Partnership


New RenataDX Screening System Delivers Fast, Accurate Results for Clinical Scientists


Stunning Weevil Eye Wins Forty-Fourth Annual Nikon Small World Competition

 

 

Can't find what you are looking for?


Search by company or by product


Company Name:

Product:





Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd